ZIM
NVCR icon

Zacks Investment Management’s NovoCure NVCR Stock Holding History

Zacks Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,700
Closed -$986K – 556
2020
Q4 		$986K Sell
5,700
-9,134
-62% -$1.25M 0.02% 349
2020
Q3 		$1.65M Sell
14,834
-6,899
-32% -$552K 0.03% 250
2020
Q2 		$1.29M Buy
21,733
+11,646
+115% +$766K 0.03% 266
2020
Q1 		$679K Buy
10,087
+2,663
+36% +$210K 0.02% 350
2019
Q4 		$626K Hold
7,424
– – 0.01% 433
2019
Q3 		$555K Buy
+7,424
New +$594K 0.01% 431

Other funds holding NVCR

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Zacks Investment Management's NVCR Position: Q1 2021 in Review

Zacks Investment Management sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 5,700 shares — an estimated $986K sold.

Zacks Investment Management first reported a position in NVCR in Q3 2019 and held it in 6 quarters. The position peaked at $1.65M in Q3 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

  • Zacks Investment Management reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
  • Zacks Investment Management sold 5,700 NovoCure shares in Q1 2021, an estimated $986K.
  • Zacks Investment Management first reported a position in NovoCure in Q3 2019 and held it in 6 quarters.
  • Zacks Investment Management's NovoCure position peaked at $1.65M in Q3 2020.
  • 327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on Zacks Investment Management's 13F filing for Q1 2021, filed 17 May 2021.